Regeneron Pharmaceuticals (REGN) Operating Margin (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Operating Margin of 30.15% for Q2 2026, up 78.0% year-over-year from 16.94% in Q2 2025, and up 69.06% quarter-over-quarter from 17.83% in Q1 2026.
Regeneron Pharmaceuticals (REGN) Operating Margin (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Operating Margin history runs 18 years deep, the most recent figure standing at 30.15% for Q2 2026.
- In Q2 2026, Operating Margin rose 78.0% year-over-year to 30.15%; the TTM figure through Jun 2026 stood at 24.74% (down 228.0% YoY), while the FY2025 annual figure was 24.95%, down 315.0% from the prior year.
- Operating Margin for Q2 2026 stood at 30.15%, up from 17.83% in the prior quarter.
- The five-year high for Operating Margin was 2517.0% in Q1 2022, with the low at 17.83% in Q1 2026.
- The 5-year median for Operating Margin is 30.04% (2023), against an average of 229.25%.
- The sharpest annual moves came in 2022 and 2023: Operating Margin soared 247300 bps in 2022, then plunged 248706 bps in 2023.
- Regeneron Pharmaceuticals' Operating Margin stood at 1146.8% in 2022, then tumbled by 98 bps to 28.33% in 2023, then decreased by 8 bps to 26.13% in 2024, then retreated by 13 bps to 22.65% in 2025, then surged by 33 bps to 30.15% in 2026.
- Business Quant data shows REGN's Operating Margin at 30.15% in Q2 2026, 17.83% in Q1 2026, and 22.65% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -25,380.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.15% |
| Mar 31, 2026 | 17.83% |
| Dec 31, 2025 | 22.65% |
| Sep 30, 2025 | 27.35% |
| Jun 30, 2025 | 29.37% |
| Mar 31, 2025 | 19.54% |
| Dec 31, 2024 | 26.13% |
| Sep 30, 2024 | 31.70% |
| Jun 30, 2024 | 30.15% |
| Mar 31, 2024 | 23.89% |
| Dec 31, 2023 | 28.33% |
| Sep 30, 2023 | 33.04% |
| Jun 30, 2023 | 32.19% |
| Mar 31, 2023 | 29.94% |
| Dec 31, 2022 | 1,146.80% |
| Sep 30, 2022 | 41.68% |
| Jun 30, 2022 | 38.85% |
| Mar 31, 2022 | 2,517.00% |
| Dec 31, 2021 | 53.31% |
| Sep 30, 2021 | 53.50% |